Idioma:

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy

Kalil, Andre C ; Freifeld, Alison G ; Lyden, Elizabeth R ; Stoner, Julie A Chêne, Geneviève

PloS one, 2009-05, Vol.4 (5), p.e5512-e5512 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por

Enviar para

Título:
Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy
Autor: Kalil, Andre C ; Freifeld, Alison G ; Lyden, Elizabeth R ; Stoner, Julie A
Chêne, Geneviève
Assuntos: Acyclovir ; Analysis ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Case-Control Studies ; Clinical trials ; Cohort Studies ; Confidence intervals ; Critical Care and Emergency Medicine/Sepsis and Multiple Organ Failure ; Cytomegalovirus ; Cytomegalovirus - drug effects ; Cytomegalovirus infections ; Cytomegalovirus Infections - drug therapy ; Cytomegalovirus Infections - prevention & control ; Disease prevention ; Drug approval ; Drug therapy ; Drugs ; Effectiveness ; Evidence-Based Medicine ; FDA approval ; Female ; Ganciclovir ; Ganciclovir - adverse effects ; Ganciclovir - analogs & derivatives ; Ganciclovir - therapeutic use ; Health aspects ; Health risks ; Heart ; Humans ; Infection ; Infections ; Infectious diseases ; Infectious Diseases/Nosocomial and Healthcare-Associated Infections ; Infectious Diseases/Viral Infections ; Internal medicine ; Liver ; Liver diseases ; Liver transplants ; Male ; Medical research ; Medicine, Experimental ; Meta-analysis ; Middle Aged ; Neutropenia ; Neutrophils ; Organ Transplantation ; Patients ; Preempting ; Prevention ; Prophylaxis ; Public health ; Randomized Controlled Trials as Topic ; Regression analysis ; Risk ; Safety ; Statistical analysis ; Studies ; Transplantation of organs, tissues, etc ; Transplants & implants ; Valacyclovir ; Valganciclovir
É parte de: PloS one, 2009-05, Vol.4 (5), p.e5512-e5512
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: AK. Performed the experiments: AK EL JS. Analyzed the data: AK AF EL JS. Contributed reagents/materials/analysis tools: AK. Wrote the paper: AK AF EL JS.
Descrição: Several anti-viral drugs have demonstrated efficacy in preventing Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients. The recently approved valganciclovir is the most commonly used and most expensive drug for CMV prevention. The safety and efficacy data have been drawn from a single trial. We hypothesized that valganciclovir may not be as safe as nor more effective than other therapies for CMV prevention. All experimental and analytical studies that compared valganciclovir with other therapies for prevention of CMV infection after SOT were selected. Based on meta-analytic and multivariate regression methodologies we critically analyzed all available evidence. Nine studies were included (N = 1,831). In trials comparing valganciclovir with ganciclovir, the risk for CMV disease is 0.98 (95% Confidence Interval (95%CI) 0.67 to 1.43; P = 0.92; I(2) = 0%). Valganciclovir was significantly associated with the risk of absolute neutropenia (<1,500/mm(3)) compared with all therapies (Odds Ratio (OR) 3.63 95%CI 1.75 to 7.53; P = 0.001; I(2) = 0%); with ganciclovir only (OR 2.88, 95%CI 1.27 to 6.53; P = 0.01; I(2) = 0%); or with non-ganciclovir therapies (OR 8.30, 95%CI 1.51 to 45.58; P = 0.01; I(2) = 10%). For a neutropenia cut-off of <1,000/mm(3), the risk remained elevated (OR 1.97, 95%CI 1.03 to 3.67; P = 0.04; I(2) = 0%). For every 24 patients who receive valganciclovir prophylaxis, one more will develop neutropenia compared to other therapies. The risk of late-onset CMV disease with valganciclovir was similar to ganciclovir and higher than those with non-ganciclovir therapies (OR 8.95, 95%CI 1.07 to 74.83; P = 0.04; I(2) = 0%]. One more patient will develop late-onset CMV disease for every 25 who receive valganciclovir compared to treatment with non-ganciclovir therapies. The risk of CMV tissue-invasive disease in liver recipients receiving valganciclovir was 4.5 times the risk seen with ganciclovir [95%CI 1.00 to 20.14] (p = 0.04). All results remained consistent across different study designs, valganciclovir doses, and CMV serostatus. Valganciclovir shows no superior efficacy and significantly higher risk of absolute neutropenia, CMV late-onset disease, and CMV tissue-invasive disease compared to other standard therapies. Due to the availability of efficacious, safer, and lower cost drugs (high-dose acyclovir, valacyclovir, ganciclovir), our results do not favor the use of valganciclovir as a first-line agent for CMV preemptive or universal prophylaxis in SOT patients.
Editor: United States: Public Library of Science
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy

Kalil, Andre C ; Freifeld, Alison G ; Lyden, Elizabeth R ; Stoner, Julie A Chêne, Geneviève

United States: Public Library of Science

Buscando em bases de dados remotas. Favor aguardar.